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Introduction
One of the most important characteristics of systemic autoimmune diseases, including idiopathic
inflammatory myopathies (IIM), is the immune response to self-antigens manifested by the pro-
duction of autoantibodies that recognize a variety of cytoplasmic and nuclear antigens. In the
last 40 years, autoantibodies of patients with IIM have been investigated; however, some of the
fundamental questions related to these antibodies remain unresolved (1).
Indirect immunofluorescence (IIF), in which HEp-2 cells are used as a substrate, is considered
the gold standard for detecting antinuclear antibodies (ANA’s) in autoimmune rheumatic diseases.
Using this method, specific antibodies that occur exclusively in these diseases were present in a great
proportion of patients with myositis (50–80%) (2). It is important to note that patients with myositis
more frequently have high titers of these antibodies than patients with overlap syndromes, and low
titers usually are present in patients with myopathies associated with neoplasia. In contrast, these
autoantibodies are usually absent in patients with inclusion body myositis, dystrophies, and other
non-autoimmune myopathies.
In general, even though the diagnostic value of these autoantibodies has been limited, they are
useful as diagnostic markers since they closely correlate with certain clinical manifestations of
disease and help identify clinical subgroups and to know about the prognosis of the IIM.
Idiopathic inflammatorymyopathies has twomajor types of autoantibody groups: (1) those found
primarily in patients suffering from polymyositis (PM) or dermatomyositis (DM) are known as
myositis-specific autoantibodies (MSAs); these are not observed in other diseases of connective
tissue and are almost completely absent in patients with muscular dystrophies and (2) those that
appear in myositis overlap syndromes and in other connective tissue diseases, which correlate with
certain clinical and/or pathophysiological conditions of myositis, are known as myositis-associated
autoantibodies (MAAs) (3).
Myositis-Specific Autoantibodies
In general, MSAs are useful markers for clinical diagnosis, classification, and for predicting the
prognosis of the IIM. MSAs have two major autoantibody subsets. Probably, the largest and most
interesting subset is the anti-cytoplasmic antibodies, which consist of two main groups: those
antibodies that are directed to various aminoacyl-tRNA synthetases (ARSs), cytoplasmic enzymes
responsible for catalyzing the esterification of a specific amino acid to its cognate tRNA, forming an
aminoacyl-tRNA. To each of the 20 amino acids corresponds a unique tRNA.
Autoantibodies against histidyl-tRNA-synthetase (anti-Jo-1) (4) are themost commonMSAs that
belong to anti-cytoplasmic antibodies and were first described in 1980.These antibodies are found
in approximately 25–30% of myositis patients, and they attach histidine to the appropriate tRNA.
The anti-Jo-1 antibodies (4) were subsequently found in a group of patients with anti-synthetase
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syndrome (5), a unique clinical syndrome that includes myositis,
interstitial lung disease (ILD), non-erosive arthritis, fever, and
characteristic hyperkeratotic lesions along the radial and palmar
aspects of the fingers known as “mechanic’s hands.”
Other antibodies from the same subgroup of anti-cytoplasmic
antibodies targeting a number of additional ARSs have since
been identified, including those recognizing threonyl-tRNA-
synthetase (anti-PL-7), alanyl-tRNA synthetase (anti-PL-12),
glycyl-tRNA synthetase (anti-EJ), isoleucyl-tRNA synthetase
(anti-OJ), asparaginyl-tRNA synthetase (anti-KS), tyrosyl-tRNA
synthetase (anti-YRS), and, most recently, phenylalanyl syn-
thetase (anti-Zo) (4). This group of autoantibodies to ARS occurs
in approximately 1–5% of patients with myositis (5). It is worth
noting that antibodies to one synthetase do not appear to cross-
react with other synthetases, but other autoantibodies may occur
with anti-synthetase, such as anti-SS-A and anti-SS-B.
The other subsets of anti-cytoplasmic antibodies are the anti-
signal-recognition particle antibodies (anti-SRP). This is a non-
synthetase antibody, and is found in approximately 4% or less
of patients with myositis. SRP is a six-polypeptide complex (72,
68, 54, 19, 14, and 9-kDa) and one 7SL RNA molecule. The
cytosolic ribonucleoprotein binds to the endoplasmic reticulum
(ER), signaling sequences of elongating polypeptide chains dur-
ing the synthesis and translocating them to the ER membrane.
This autoantibody was first described in 1986 in a “typical PM”
patient (6).
Later work showed that autoantibodies could be directed to
any of the six polypeptides, as well as to 7SL RNA. The clinical
features in the majority of patients with anti-SRP antibodies are
unusually severemuscle weakness, dysphagia, and high creatinine
kinase levels; poor response to steroids; and a worse prognosis
compared to that in patients with other myositis. Furthermore,
a large amount of necrotic and regenerating fibers were found
in muscle biopsies taken from these patients, who also showed
a lower frequency of lymphocytic inflammation than patients
affected by other myositis (7).
The other group of MSAs is ANA, which occurs more fre-
quently (approximately 60%) than anti-cytoplasmic antibodies,
and it shows a homogeneous, speckled, or nucleolar pattern. Anti-
Mi-2 is the only ANA that is also considered a MSA and was
first described in 1976 (8). In 1995, their cognate antigens were
cloned and autoantibodies to Mi-2 immunoprecipitated a nuclear
complex consisting of up to eight subunits. Currently there are two
known protein targets,Mi-2α (240-kDa) andMi-2β (218-kDa), of
the Mi-2 antigen.
Both forms of Mi-2 are different molecules that contain a set
of helicase motifs with a similar function as nuclear helicases.
Mi-2β and histone deacetylases form a protein complex called
nucleosome-remodeling deacetylase complex, (9) which may be
involved in gene transcription through histone acetylation, caus-
ing a remodeling of the nucleosome structure. In most studies,
an antibody to Mi-2 has been associated with DM in adult and
juvenile patients. It is rarely present in PM and leads to fewer
complications related to ILD. In general, patients who have Mi-2
have a good prognosis and show good response to therapy.
A number of other MSAs have been described in different
populations of patients with myositis. Clinical usefulness of these
autoantibodies has been identified in patients with amyopathic
DM and malignant-associated myositis.
In 2005, a specific autoantibody was identified in patients with
clinically amyopathic DM (C-ADM), which is a term suggested
for patients with typical DM rashes for at least 2 years, but without
muscle symptoms. In the early 1990s, these patients were consid-
ered to haveDMsinemyositis. This specific antibodywas detected
in eight of 15 patients (53%) with C-ADM by immunoprecipita-
tion and immunoblotting. This antibodywas termed anti-CADM-
140, since it precipitated a 140-kDa protein.
Typical DM rashes were found in the eight patients who had
anti-CADM-140 in this study; however, they showed no muscle
weakness or muscular pain and had normal serum creatinine
kinase levels. In another study of 15 patients who had C-ADM,
13 of them developed ILD; of these, five developed an acute
progressive type of ILD. Four of these patients had anti-CADM-
140. Therefore, antibody to CADM-140 may serve as a specific
serologic marker for patients with myositis and acute ILD (10).
In subsequent studies, the target antigen of CADM-140 was
identified using HeLa cell-derived complimentary DNA (cDNA)
library. Specifically, the antibody reacted with the “melanoma
differentiation-associated gene 5” (MDA-5) which encodes an
RNA helicase that plays important roles in the innate immune
system during RNA virus infection. The protein was expressed in
cells transfected with full-length MDA-5 cDNA, confirming the
identity ofMDA-5 as the CADM-140 autoantigen.
In addition, an ELISA using recombinant MDA-5 protein as
the antigen showed an analytical sensitivity of 85% and analytical
specificity of 100% compared with the results of the “gold stan-
dard” immunoprecipitation assay. The antigen was also useful for
identifying patients with C-ADM and/or rapidly progressive ILD
(11). By using indirect IIF, this antibody shows granular or retic-
ular cytoplasmic staining resembling cytoskeletal components.
Targoff et al. described a previously unknown autoantibody
that recognizes a 155-kDa protein (p155) in patients with DM.
This antibody is present mainly in patients with adult and juvenile
DM and, interestingly, in patients with cancer-associated DM.
Since it was present only in one patient with systemic lupus ery-
thematosus (SLE) among a large group of non-myositis controls,
this is considered a DM-specific antibody (12).
In another study, Targoff determined that the transcriptional
intermediary factor 1-γ (TIF1-γ) is the target antigen of anti-
p155 antibody. Interestingly, intracytoplasmic systems of protein
translation are the primary immunological targets of PM-specific
autoantibodies, while the targets of DM-specific autoantibodies
are nuclear transcription factors. This suggests that PM and DM
have different pathogenic mechanisms or different production
systems of MSAs.
A Japanese group studying 52 myositis patients found an
autoantibody that immunoprecipitated 155- and 140-kDa pro-
teins in seven of them (13%). These patients (anti-p155/p140-
positive) showed more frequent typical DM rashes than the other
patients, but none had ILD. This autoantibody seems to be the
same as the autoantibody to p155 reported by Targoff et al. How-
ever, the Japanese group claims they are not the same, since the
155-kDa band was always associated with a 140-kDa band in their
study.
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TABLE 1 | Autoantibodies in myositis, their target antigens, M.W., frequency, and clinical significance.







anti-Jo-1 Histidyl-tRNA synthetase 50/52 15–20 Antisynthetase syndrome (myositis, interstitial lung
disease, polyarthritis, mechanic’s hand Raynaud’s
phenomenon, fever)
anti-PL-7 Threonyl-tRNA synthetase 83 5–10
anti-PL-12 Alanyl-tRNA synthetase 70 <5
anti-EJ Glycyl-tRNA synthetase 75 5–10
anti-OJ Isoleucyl-tRNA synthetase 145 <5
anti-KS Asparaginyl-tRNA synthetase 63 <5
anti-Zo Phenylalanyl-tRNA synthetase 52 <1
anti-YRS Tyrosyl-tRNA synthetase 59 <1
anti-SRP Signal recognition particle 9–72 <4 Necrotizing myopathy
anti-Mi-2 Mi-2α/Mi-2β helicase family proteins 240/218 5–10 Dermatomyositis
anti-CADM-140 Melanoma differentiation-associated gene 5 (MDA-5) 140 50 (C-ADM) Specific in C-ADM and acute ILD
Anti-p155(/p140) Transcriptional intermediary factor 1γ (TIF1-γ) 155/140 20 (DM) Dermatomyositis, especially in cancer-associated
dermatomyositis
anti-MJ Nuclear matrix protein (NXP-2) 140 <23 Juvenile dermatomyositis
anti-PMS1 DNA repair mismatch enzyme 120 7.5 DM and PM
anti-SAE Small ubiquitin-like modifier activating enzyme 40/90 <4 Dermatomyositis
anti-HMGCR HMG-CoA reductase 200/100 62% Statin-induced autoimmune-necrotizing myopathy
MYOSITIS-ASSOCIATED AUTOANTIBODIES (MAAs)
anti-U1RNP U1 small nuclear RNP 11–70 10 Overlap myositis, MCTD
anti-SS-A/Ro Ro-52/TRIM21 and Ro-60 proteins 52/60 35% ILD in IIM patients
anti-Ku DNA-PK regulatory subunit 70/80 20–30 Polymyositis–SSc overlap in Japanese
anti-PM-Scl Nucleolar protein complex of 11–16 proteins 75/100 10–15 Polymyositis–SSc overlap
ARS, aminoacyl-tRNA synthetases; C-ADM, clinically amyopathic dermatomyositis; ILD, interstitial lung disease; HMGCR, 3-hydroxy-3 methylglutaryl-coenzyme A reductase; DNA-PK,
DNA-dependent protein kinase; MCTD, mixed connective tissue disease; SSc-scleroderma. MW, molecular weight; kDa, kilodalton.
A preliminary study of United States patients with juvenile DM
described a new anti-MJ antibody that targets a 140-kDa protein.
It was identified as nuclear matrix protein NXP-2 (13). Moreover,
Gunawardena et al., studying UK patients with juvenile DM,
found an autoantibody to a 140-kDa protein that was identical to
the anti-MJ (anti-NXP-2) antibody. They screened 162 juvenile
myositis patients and found 23% of them positive for anti-NXP-
2 antibody. The autoantibody was detected only in patients with
juvenile DM. It has been confirmed that this antibody is different
from anti-CADM-140 and anti-p155.
Betteridge et al. (14) reported a new autoantibody against small
ubiquitin-like modifier activating enzyme (SAE) in patients with
DM. The post-translational modification of specific proteins such
as protein kinases and transcription factors is greatly influenced by
small ubiquitin-like modifiers. The authors studied 266 patients
with myositis, 250 with other rheumatic diseases, and 50 healthy
controls. Of these, 11 (4%) had anti-SAE, which immunoprecip-
itated both 40 and 90 kDa proteins; all of these patients suffered
from DM and showed classical skin lesions (13).
A new autoantibody associated with necrotizing myopathy was
also described by Christopher-Stine et al. in a preliminary report.
The authors studied immunoprecipitations from 35 S-methionine-
labeledHeLa cell lysates of 225 patientswithmyositis and reported
necrosis on muscle biopsy in 38 patients but no perifascicular
atrophy or red-rimmed vacuoles; 26 patients showed unidentified
MSAs (15).
In 16 of these 26 patients, an anti-200/100 antibody, which
immunoprecipitated both 200-and 100-kDa proteins, was found.
In subsequent studies, the 100-kDa autoantigen was identi-
fied as the 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMGCR), the pharmacologic target of statin medications. Addi-
tional experiments indicated that the 200-kDa autoantigen is the
dimeric form of HMGCR (15).
The majority of these patients (63%) had a history of expo-
sure to statins prior to developing muscle weakness. It is not
clear if exposure to this drug intensifies this myopathy, but these
results may provide useful information on the immune-mediated
mechanisms of necrotizing myopathy.
A list of these MSAs and MAAs is outlined in Table 1.
Myositis-Associated Autoantibodies
The more common MAAs includes anti-U1-RNP, anti-SS-A/Ro,
anti-PM/Scl, and anti-Ku, which are found in patients withmyosi-
tis and various overlap syndromes (16).
U1-RNP is a small nuclear ribonucleoprotein consisting of
U1-snRNA and nine proteins: 70 K (70-kDa), A (34-kDa),
B’/B (29/28-kDa), C (22-kDa), D (16-kDa), E (13-kDa), F
(12-kDa), and G (11-kDa). It is part of a spliceosome that
eliminates intervening sequences from pre-mRNA to pro-
duce mature mRNA. Anti-U1-RNP antibody is a serologi-
cal marker for mixed connective tissue disease, very common
in definite scleroderma (SSc), SLE, PM/DM, and overlapping
syndromes.
Anti-SS-A/Ro antibody is found in some autoimmune
diseases such as Sjögren’s syndrome, SLE, SSc, and IIM. Anti-
SS-A/Ro recognizes two distinct antigens, with molecular
weights of 52-kD (Ro-52/TRIM21) and 60-kDa (Ro-60),
respectively. Each antibody has a different clinical association.
Anti-Ro-52/TRIM21 is significantly more prevalent in SSc and
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myositis than anti-Ro-60, while isolated anti-Ro-52/TRIM21may
be found in up to 37% of patients with myositis, often in
correlation with anti-Jo-1 reactivity. The presence of anti-SS-
A/Ro-52/TRIM21 antibodies is associated with more severe ILD,
particularly in patients with anti-synthetase syndrome (13).
Anti-PM/Scl antibodies are a heterogeneous group of autoan-
tibodies directed to several proteins of the nucleolar PM/Scl
macromolecular complex. PM/Scl-75 and PM/Scl-100 are the two
main autoantigenic protein components and are named based
on their apparent molecular weights. These antibodies are asso-
ciated with PM-SSc overlap syndrome in approximately 15%
of the patients, and may be present also in other autoimmune
diseases (16).
The antibody to Ku was reported for the first time in Japanese
patients suffering from PM-SSc overlap syndrome, and it was
considered a serologic marker of it. However, studies carried out
in other countries have yielded different results. In the United
States, anti-Ku antibody was found mostly in SLE patients. The
difference in the results may be due to the use of different assay
systems and the differences in ethnic or genetic background of
the patients studied (16). The target antigen of anti-Ku antibody
is a heterodimer of 70- and 80-kDa proteins that is thought to be
an activation subunit of DNA-dependent protein kinase. The Ku
antigen has key roles in various cellular processes, including DNA
double-strand break repair.
Conclusion
In the last 20 years, several MSAs and MAAs, and their target
autoantigens, clinical phenotypes, and histological features have
been identified. This group of autoantibodies may yield useful
insights into their diagnosis, prognosis, and treatments.
Testing for the majority of these autoantibody specificities is
already commercially available through different immunoassays.
These methods aid to establish the correct diagnosis in cases in
which an autoimmune muscle disease is suspected.
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